Text Version |Site map | Contact Us | Temple University | FAQs | Search
Prospective Students | Current Students | Faculty/Preceptors | Alumni

Why Temple School of Pharmacy

Read more...
cGMP Services
cGMP Services
Moulder Center
QA/RA

Faculty & Staff Directory

 

Magid Abou-Gharbia, Ph.D., FRSC

Associate Dean for Research

Laura H. Carnell Professor of Medicinal Chemistry

Director of the Moulder Center for Drug Discovery Research

 

3307 N. Broad Street

Philadelphia, PA 19140

office Room 515

phone (215) 707-4949

email magid.abougharbia@temple.edu

Biosketch | Selected Publications | Posters

 

[download as PDF ]

 

Magid Abou-Gharbia, Ph.D., FRSC is currently the Associate Dean for Research, Laura H. Carnell Professor of Medicinal Chemistry and Director of the Moulder Center for Drug Discovery Research (MCDDR) at the School of Pharmacy, Temple University, Philadelphia, PA. He is responsible for Setting and implementing School of Pharmacy research strategies to promote the school’s research and entrepreneurial enterprise. Prior to joining Temple University in 2008, Magid spent 26 years at Wyeth Pharmaceuticals where he was senior Vice President and Head of Chemical and Screening Sciences. As Senior Vice President & Head of Chemical & Screening Sciences at Wyeth, he was responsible for overseeing and directing Wyeth chemistry and screening research efforts of 500 scientists at four US research facilities and 150 chemists in Hyderabad, India in support of drug discovery in Neuroscience, Inflammation, Women's Health/Bone, Oncology and Cardio-vascular/Metabolic Diseases therapeutic areas.

 

Education: BS in Pharmacy and Pharmaceutical Sciences (1971), MS in Medicinal Chemistry (1974) from the School of Pharmacy, Cairo University, and Ph.D. (1979) from the University of Pennsylvania working with Professor Madeleine Joullie, followed by a two-year NIH Postdoctoral fellowship at Temple University Medical School and the department of chemistry.

 

Pharma R&D Achievements: Over the years Dr. Abou-Gharbia's group research efforts at Wyeth led to the discovery of eight marketed drugs and many compounds currently under clinical evaluation. List include: the first-in-class antidepressants Effexor® and Pristiq®; the anticancer agent Mylotarg®; an anticancer rapamycin derivative, Torisel™ (temsirolimus); a short-acting hypnotic Sonataa®, a broad spectrum antibiotic Tygacil®, anticancer kinase inhibitor Bosutinib®, and a non-steroidal, HRT Viviant™, (Bazedoxifene®).

 

Research Interests: Manipulation of synthetic approaches in the design and synthesis of biologically active agents. Methodologies included: 1, 3-dipolar cycloaddition reactions, Claisen's rearrangement, Diels-Alder reactions, chemistry of ketenes, sulfilimines, synthesis of substituted steroids. Use of receptor homology, bioisoteric replacement strategies, rational and structure-based drug design approaches Utilizing natural products as a unique resource for discovering innovation therapeutics. Applying enabling technology platforms to evaluate drug-like properties of all discovered molecules to ensure clinical effectiveness of drug candidates. Design of chemical probes in support of translation medicine.


Scientific Contributions include over 275 invited lectures, presentations and publications; inventor on 110 US patents and over 350 patents worldwide. Awards and Honors include: Laura H. Carnell Professor (2013), ACS Henry Whalen Jr. Award in Business Development (2011); Induction to ACS Medicinal Chemistry Hall of Fame (2008); ACS Heroes of Chemistry (2008); Alfred Burger Award in Medicinal Chemistry (2008); Science and Technology Medal from the R&D Council of New Jersey (2008); selected among the Top 10 Scientists in New Jersey by New Jersey Business Magazine (2008); American Institute of Chemists (AIC) Chemistry Pioneer Award (2007); Fellow of the Royal Society of Chemistry (FRSC 2006); Researcher of the Year (2006) from Health Care Institute of NJ (HINJ); Trailblazer Award (2006) from Science Spectrum; Induction into the New Jersey Inventors Hall of Fame (2004); The Procter Medal (2003); ACS Earle B. Barnes Award (2001); Philadelphia Organic Chemists Club (POCC) Award (2001); Egyptian Pharmaceutical Society Drug Discovery Award (2000); Named as one of the most Prolific Inventors of the Decade by US Patent & Trade Mark (1998); ACS-Philadelphia Section Award (1997); Wyeth-Ayerst Exceptional Achievement Award (1992); and others.

 

Scientific and Professional Activities include membership of the SAB of Chemistry Department, SAB of Galenea, University of Pennsylvania, SAB of Abbott pharmaceutical, the 2009 EPSRC International Review Panel responsible for evaluating the impact of chemical research in the UK; Fellow of the Royal Society of Chemistry (FRSC); member of Advisory Board of Galenea Pharmaceutical, Laxai, Dow's Women Scientists; Board of Visitors of College of Science and Technology (CST) , Temple University; C&E News Advisory Board; and on the editorial and scientific advisory boards of many journals.

 

Leadership and Mentoring: Throughout the course of his career, Dr. Abou-Gharbia has worked tirelessly with organizations across the globe in an effort to establish and implement modern paradigms for drug discovery and to promote biomedical research. His efforts were instrumental in the formation of the Moulder Center for Drug Discovery Research, a unique fully integrated drug discovery research center within Temple University's School of Pharmacy. Focused on the education and career development of the next generation of drug discovery scientists, the Moulder Center provides a hands-on experiential education in modern methods of drug discovery and development. Faculty, students, and staff scientists work together to foster both the next generation of research and cutting edge drug research through collaboration with a global network of top in class academic, public, and private institutions.

Among his recent contributions in the Middle East are the establishment of Qatar Biomedical Research Institute (QBRI), instituting medicinal chemistry and drug discovery research at four major educational institutions in the region: the University of Sharja's School of Pharmacy in the UAE, the Misr University for Science and Technology (MUST) in Egypt, Future University in Egypt (FUE) and City of Scientific Research and Technological Applications (SERTA-City) in Egypt.

 

Academic Appointments: Professor of Chemistry, College of Science and Technology (CST) at Temple University, Visiting Professor, Wolfson Centre for Age Related Diseases, School of Biomedical and Health Sciences, King's College London, Adjunct Professor of Medicinal Chemistry, Northeastern University, Center of Drug Discovery (CDD), Cairo University and the University of Ferrara, IT.

 

* 2011 Commencement Speech